Nautilus (Nasdaq: NAUT) is a company with a vision to revolutionize biomedicine by unlocking the complexity of the human proteome. We are driven to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across biomedical research and drug discovery.
We were founded in 2016 on the belief that incremental advancements to existing technologies are inadequate; that a bold scientific leap would be required to radically reinvent proteomics and create a new gold standard in the field.
Our mission is to integrate our breakthrough innovations in computer science, engineering, and biochemistry to develop a protein analysis platform of extreme sensitivity and scale. Pursuing that goal is a leadership team with a unique combination of experiences from the fields of technology and life sciences, and a broader team made up of a wide spectrum of disciplines and expertise including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticians, and software engineers.
Nautilus exists to pursue deep, hard science and, ultimately, to positively impact the health of millions around the world.
Founder & CEO
Sujal Patel is a successful technology entrepreneur and executive who founded and served as CEO of Isilon Systems, an enterprise data storage company. In 2006, Isilon completed one of the most successful initial public offerings of the year. Isilon was acquired by EMC in 2010 for $2.6 Billion, the largest acquisition in EMC’s history. Sujal served as the President of EMC’s Isilon Storage Division from the acquisition until 2012, driving significant revenue growth, market expansion and organizational scale. He graduated from the University of Maryland College Park in 1996 with a degree in Computer Science.
Parag Mallick, PhD
Founder & Chief Scientist
Dr. Parag Mallick is an Associate Professor at Stanford University, and an interdisciplinary scientist, who has developed multi-scale approaches to accelerate the discovery of diagnostic and prognostic protein biomarkers. Parag trained with pioneering researcher Ruedi Aebersold in clinical proteomics and systems biology at the Institute for Systems Biology. Parag holds a BS degree in Computer Science from Washington University in St. Louis, and a PhD in Chemistry & Biochemistry from UCLA. He has over 75 publications and holds patents in the fields of artificial intelligence, proteomics technology, biomarker development, and nanotechnology.
Chief Financial Officer
Anna is an experienced finance and business leader who joins Nautilus from Igneous where she served as VP of Finance and Operations with responsibility for finance, accounting, people, legal, and operations. Previously, Anna held a variety of roles at companies including Amazon Web Services and Isilon Systems, where she ultimately led the finance and sales operations organization. Anna has a BS in Biochemistry from Western Washington University and started her career at the Fred Hutchinson Cancer Research Institute. She earned her MBA from the University of Washington, leading her into a variety of finance and business roles of escalating responsibility.
Chief Business Officer
Nick Nelson has extensive leadership experience with top-tier diagnostics, therapeutics and life science companies. Before joining Nautilus, he was Chief Business Officer at Caris Life Sciences where he led all business development and strategic partnerships. Prior to Caris, he was Vice President of Commercial and Corporate Development at Trovagene (now Cardiff Oncology), and before that spent ten years at Illumina. While at Illumina he held leadership positions in the New and Emerging Markets business where he established partnerships and collaborations enabling high-growth genomics businesses. He received his Bachelor of Science degree in Cellular and Molecular Biology from San Diego State University.
Chief People Officer
Gwen has more than 25 years of senior leadership in human resources, organizational culture, and business strategy. She previously held the positions of Vice President of Global People and Infrastructure at Isilon Systems for more than six years and General Manager of Human Resources at Microsoft Corporation for nearly twenty years, leading Microsoft’s human resources agenda for its various groups and overseeing worldwide recruiting and alternative staffing. Ms. Weld studied business administration at Pace University.
SVP of Operations
Mary Godwin is a proven Operations and Supply Chain executive with deep experience across large corporations and smaller start ups. She brings to Nautilus deep experience developing processes and business relationships that improve both corporate metrics and financial performance. Before joining Nautilus, Mary held similar roles at Qumulo and Isilon Systems, where she built and scaled an operations function that supported over $1B in annual revenue. Prior experience included senior operational roles at Apple, Philips Electronics, and Lucent Technologies. She holds a Bachelor of Science degree in Plastics Engineering from the University of Massachusetts Lowell, and an MBA from Santa Clara University.
Subra Sankar, PhD
SVP of Product Development
Subra is a seasoned product and engineering leader who joins Nautilus from GenapSys where he served as SVP of Product Development, leading the company’s R&D efforts including Engineering, Assay, System Integration, Consumable Development, Informatics and a variety of chemistry and molecular biology groups. Subra has held many senior roles over the last 15 years, notably at Solexa/Illumina where, from 2006 to 2012, he led instrument and consumable development efforts for next gen sequencers and related products. Subra has a Ph.D. in Aerospace Engineering from Georgia Tech and an MBA from UC Berkeley.
Matthew Murphy, Esq.
Matt has spent over a quarter century advising companies on the cutting edge of life sciences technologies. He has held numerous General Counsel roles over this period, including most notably at Pacific Biosciences and 10X Genomics. He specializes in creating and defending industry defining patent portfolios, and in building and leading legal operations that help develop, finance and commercialize high growth companies. Matt received his Bachelor of Science in Microbiology and Fermentation Science from the University of California, Davis, and a Juris Doctorate from the University of San Francisco School of Law.
VP of Corp Marketing & Comms
Chris is a proven marketing leader who joins Nautilus from Smartsheet where he served as VP of Marketing and Communications with responsibility for creating markets, building awareness, and driving revenue. Prior to that, he led marketing and communications at ExtraHop Networks and Isilon Systems through the company’s acquisition by EMC. At EMC/Isilon, he served as executive sponsor of the company’s Life Sciences and Genomics markets, leading product evangelism, market research, and sales preparedness. Chris holds a BS from Syracuse University.
Ken Kuhn, PhD
VP of Reagent and Platform Development
An experienced R&D, product development, and operations executive, Dr. Kuhn served as Vice President of Systems Integration, Product Development and Operations, at Encodia and as Senior Director of Product Development at Illumina, where he played a significant early role in developing and commercializing a range of NGS, genotyping, gene expression, and qPCR systems. Dr. Kuhn holds a Ph.D. in microbiology and immunology from Stanford University and a B.S. in biochemistry and molecular biology from Drexel University.
Sheri Wilcox, PhD
VP of Affinity Reagent Development
Sheri spent 21 years at SomaLogic where she was instrumental in the development of the SomaScan Platform and SOMAmer reagents. As Associate Director of Aptamer Discovery she guided research of aptamers for biomarker discovery and directed the high-throughput generation of SOMAmer reagents, and as Senior Director of Analytical and Discovery Sciences, led SOMAmer discovery and characterization efforts, as well as several collaborations. Before joining SomaLogic, she was a postdoctoral fellow at Pharmacia, prior to its merger with Pfizer Inc. Dr. Wilcox received her B.S. in chemistry from Vanderbilt University, and her Ph.D. in macromolecular and cellular structure and chemistry from Scripps Research.
Ruedi Aebersold, PhD
Professor of Systems Biology
Institute of Molecular Systems Biology in ETH Zurich (IMSB)
- Pioneer in the field of proteomics
- Co-founder of several companies and head of the biology/disease branch of the human proteome project
Lee Hartwell, PhD
President and Director Emeritus
Fred Hutchinson Cancer Research Center
- Discovered protein molecules that control the division of cells
- 2001 Co-recipient Nobel Prize in Physiology and Medicine
Joshua LaBaer, MD, PhD
Biodesign Institute at Arizona State University
- Leading researcher in cancer and personalized medicine
- Inventor of the novel protein microarray technology, Nucleic Acid Programmable Protein Array (NAPPA), which has been used widely for biomedical research
Emma Lundberg, PhD
- Professor in cell biology proteomics at KTH Royal Institute of Technology, Sweden
- Pioneer in the field of spatial proteomics
- Advocate of citizen science, advancing the use of gaming for science and health applications